Zoetis Inc. $ZTS Shares Sold by Raub Brock Capital Management LP

Raub Brock Capital Management LP lowered its stake in Zoetis Inc. (NYSE:ZTS) by 1.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 84,468 shares of the company’s stock after selling 1,311 shares during the period. Zoetis makes up approximately 2.9% of Raub Brock Capital Management LP’s portfolio, making the stock its 20th biggest holding. Raub Brock Capital Management LP’s holdings in Zoetis were worth $13,173,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of Zoetis by 0.5% in the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock valued at $6,842,222,000 after buying an additional 189,287 shares in the last quarter. Polen Capital Management LLC boosted its stake in shares of Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after buying an additional 1,313,653 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Zoetis by 1.2% in the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock valued at $1,071,032,000 after buying an additional 78,508 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Zoetis by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after buying an additional 109,791 shares in the last quarter. Finally, Brown Advisory Inc. boosted its stake in shares of Zoetis by 7.6% in the first quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock valued at $725,866,000 after buying an additional 312,746 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ZTS. Piper Sandler boosted their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research report on Saturday, September 27th. Argus reiterated a “buy” rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, Zoetis currently has a consensus rating of “Moderate Buy” and an average target price of $200.88.

Zoetis Stock Down 1.7%

Shares of NYSE:ZTS opened at $142.91 on Wednesday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $196.55. The stock’s fifty day simple moving average is $149.52 and its 200-day simple moving average is $154.82. The company has a market capitalization of $63.33 billion, a P/E ratio of 24.60, a P/E/G ratio of 2.33 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the prior year, the business earned $1.56 earnings per share. The business’s revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.